{"id":1784,"date":"2022-11-02T19:35:47","date_gmt":"2022-11-02T19:35:47","guid":{"rendered":"https:\/\/blogs.bmj.com\/jmg\/?p=1784"},"modified":"2026-02-23T00:37:57","modified_gmt":"2026-02-23T00:37:57","slug":"the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2","status":"publish","type":"post","link":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/","title":{"rendered":"The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 (Contributed by Sue Philpott)"},"content":{"rendered":"<p>Women with inherited BRCA1\/2 gene alterations are at high risk of ovarian cancer, so usually opt for surgery to remove their ovaries and tubes. Many women delay surgery to complete families or avoid premature menopause. This study confirmed previous research showing that a 4-monthly blood test can detect ovarian cancer at earlier stages, resulting in less complex surgery, a high chance of removing all visible cancer, and cost-savings to the UK health service. Surveillance should be viewed strictly as short-term, as it cannot prevent cancer, and delaying surgery could result in women being diagnosed with an incurable ovarian cancer. (<a href=\"https:\/\/jmg.bmj.com\/content\/early\/2022\/10\/10\/jmg-2022-108741\">https:\/\/jmg.bmj.com\/content\/early\/2022\/10\/10\/jmg-2022-108741<\/a> )<\/p>\n<p><a href=\"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/ar-photo\/\" rel=\"attachment wp-att-1785\"><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-1785\" src=\"https:\/\/blogs.bmj.com\/jmg\/files\/2022\/11\/AR-photo-300x200.jpg\" alt=\"\" width=\"300\" height=\"200\" srcset=\"https:\/\/blogs.bmj.com\/jmg\/files\/2022\/11\/AR-photo-300x200.jpg 300w, https:\/\/blogs.bmj.com\/jmg\/files\/2022\/11\/AR-photo-1024x683.jpg 1024w, https:\/\/blogs.bmj.com\/jmg\/files\/2022\/11\/AR-photo-768x512.jpg 768w, https:\/\/blogs.bmj.com\/jmg\/files\/2022\/11\/AR-photo-1536x1024.jpg 1536w, https:\/\/blogs.bmj.com\/jmg\/files\/2022\/11\/AR-photo-2048x1365.jpg 2048w, https:\/\/blogs.bmj.com\/jmg\/files\/2022\/11\/AR-photo-640x427.jpg 640w\" sizes=\"auto, (max-width: 300px) 100vw, 300px\" \/><\/a><\/p>\n<p>the lead clinician on the trial Mr Adam Rosenthal<!--TrendMD v2.4.8--><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Women with inherited BRCA1\/2 gene alterations are at high risk of ovarian cancer, so usually opt for surgery to remove their ovaries and tubes. Many women delay surgery to complete families or avoid premature menopause. This study confirmed previous research showing that a 4-monthly blood test can detect ovarian cancer at earlier stages, resulting in [&#8230;]<\/p>\n<p><a class=\"btn btn-secondary understrap-read-more-link\" href=\"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/\">Read More&#8230;<\/a><\/p>\n","protected":false},"author":123,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-1784","post","type-post","status-publish","format-standard","hentry","category-uncategorized"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 (Contributed by Sue Philpott) - JMG Contact blog<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 (Contributed by Sue Philpott) - JMG Contact blog\" \/>\n<meta property=\"og:description\" content=\"Women with inherited BRCA1\/2 gene alterations are at high risk of ovarian cancer, so usually opt for surgery to remove their ovaries and tubes. Many women delay surgery to complete families or avoid premature menopause. This study confirmed previous research showing that a 4-monthly blood test can detect ovarian cancer at earlier stages, resulting in [...]Read More...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/\" \/>\n<meta property=\"og:site_name\" content=\"JMG Contact blog\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-02T19:35:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-23T00:37:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/blogs.bmj.com\/jmg\/files\/2022\/11\/AR-photo-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1707\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"hqqu\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@HuiQiQu\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"hqqu\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/02\\\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/02\\\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\\\/\"},\"author\":{\"name\":\"hqqu\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\"},\"headline\":\"The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 (Contributed by Sue Philpott)\",\"datePublished\":\"2022-11-02T19:35:47+00:00\",\"dateModified\":\"2026-02-23T00:37:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/02\\\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\\\/\"},\"wordCount\":144,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/02\\\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2022\\\/11\\\/AR-photo-300x200.jpg\",\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/02\\\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/02\\\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/02\\\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\\\/\",\"name\":\"The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 (Contributed by Sue Philpott) - JMG Contact blog\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/02\\\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/02\\\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2022\\\/11\\\/AR-photo-300x200.jpg\",\"datePublished\":\"2022-11-02T19:35:47+00:00\",\"dateModified\":\"2026-02-23T00:37:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/02\\\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/02\\\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/02\\\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2022\\\/11\\\/AR-photo-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2022\\\/11\\\/AR-photo-scaled.jpg\",\"width\":2560,\"height\":1707},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/2022\\\/11\\\/02\\\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 (Contributed by Sue Philpott)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#website\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"name\":\"JMG Contact blog\",\"description\":\"JMG Contact blog\",\"publisher\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#organization\",\"name\":\"JMG Contact blog\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"contentUrl\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/files\\\/2017\\\/10\\\/blog-logo-jmg.png\",\"width\":300,\"height\":34,\"caption\":\"JMG Contact blog\"},\"image\":{\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/#\\\/schema\\\/person\\\/be0250f8d5b52412c3e7c222dabd591b\",\"name\":\"hqqu\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g\",\"caption\":\"hqqu\"},\"description\":\"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.\",\"sameAs\":[\"https:\\\/\\\/x.com\\\/HuiQiQu\"],\"url\":\"https:\\\/\\\/blogs.bmj.com\\\/jmg\\\/author\\\/hqiqu\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 (Contributed by Sue Philpott) - JMG Contact blog","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/","og_locale":"en_US","og_type":"article","og_title":"The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 (Contributed by Sue Philpott) - JMG Contact blog","og_description":"Women with inherited BRCA1\/2 gene alterations are at high risk of ovarian cancer, so usually opt for surgery to remove their ovaries and tubes. Many women delay surgery to complete families or avoid premature menopause. This study confirmed previous research showing that a 4-monthly blood test can detect ovarian cancer at earlier stages, resulting in [...]Read More...","og_url":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/","og_site_name":"JMG Contact blog","article_published_time":"2022-11-02T19:35:47+00:00","article_modified_time":"2026-02-23T00:37:57+00:00","og_image":[{"width":2560,"height":1707,"url":"https:\/\/blogs.bmj.com\/jmg\/files\/2022\/11\/AR-photo-scaled.jpg","type":"image\/jpeg"}],"author":"hqqu","twitter_card":"summary_large_image","twitter_creator":"@HuiQiQu","twitter_misc":{"Written by":"hqqu","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/#article","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/"},"author":{"name":"hqqu","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b"},"headline":"The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 (Contributed by Sue Philpott)","datePublished":"2022-11-02T19:35:47+00:00","dateModified":"2026-02-23T00:37:57+00:00","mainEntityOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/"},"wordCount":144,"commentCount":0,"publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2022\/11\/AR-photo-300x200.jpg","inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/","url":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/","name":"The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 (Contributed by Sue Philpott) - JMG Contact blog","isPartOf":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#website"},"primaryImageOfPage":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/#primaryimage"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/#primaryimage"},"thumbnailUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2022\/11\/AR-photo-300x200.jpg","datePublished":"2022-11-02T19:35:47+00:00","dateModified":"2026-02-23T00:37:57+00:00","breadcrumb":{"@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/#primaryimage","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2022\/11\/AR-photo-scaled.jpg","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2022\/11\/AR-photo-scaled.jpg","width":2560,"height":1707},{"@type":"BreadcrumbList","@id":"https:\/\/blogs.bmj.com\/jmg\/2022\/11\/02\/the-avoiding-late-diagnosis-of-ovarian-cancer-aldo-project-a-pilot-national-surveillance-programme-for-women-with-pathogenic-germline-variants-in-brca1-and-brca2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/blogs.bmj.com\/jmg\/"},{"@type":"ListItem","position":2,"name":"The avoiding late diagnosis of ovarian cancer (ALDO) project; a pilot national surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 (Contributed by Sue Philpott)"}]},{"@type":"WebSite","@id":"https:\/\/blogs.bmj.com\/jmg\/#website","url":"https:\/\/blogs.bmj.com\/jmg\/","name":"JMG Contact blog","description":"JMG Contact blog","publisher":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/blogs.bmj.com\/jmg\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/blogs.bmj.com\/jmg\/#organization","name":"JMG Contact blog","url":"https:\/\/blogs.bmj.com\/jmg\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/","url":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","contentUrl":"https:\/\/blogs.bmj.com\/jmg\/files\/2017\/10\/blog-logo-jmg.png","width":300,"height":34,"caption":"JMG Contact blog"},"image":{"@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/blogs.bmj.com\/jmg\/#\/schema\/person\/be0250f8d5b52412c3e7c222dabd591b","name":"hqqu","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/920bc4e81500cde88def4bfd7775029cb154e422c5460b9cf80d5c47137d6f35?s=96&d=mm&r=g","caption":"hqqu"},"description":"Huiqi Qu has a background as a physician trained in internal medicine and a PhD in Experimental Medicine (Endocrinology). His research applies human genetics and multi-omics to complex and pediatric diseases, including GWAS, polygenic risk scores (PRS), single-cell transcriptomics, and integrative genomics to support precision medicine and clinical translation.","sameAs":["https:\/\/x.com\/HuiQiQu"],"url":"https:\/\/blogs.bmj.com\/jmg\/author\/hqiqu\/"}]}},"_links":{"self":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1784","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/users\/123"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/comments?post=1784"}],"version-history":[{"count":0,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/posts\/1784\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/media?parent=1784"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/categories?post=1784"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.bmj.com\/jmg\/wp-json\/wp\/v2\/tags?post=1784"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}